In the case of MV140, a polyvalent inactivated whole cell bacterial sublingual tablet vaccine used to prevent recurrent urinary tract infections, human dendritic cells are activated by spleen tyrosine kinase (Syk) and MyD88-dependent signaling, leading to NF-kB and p38 MAPK activation that drives TH1, TH17, and IL-10, producing T cell differentiation and underpinning its clinical efficacy [113]. Here, SYK is linked to urinary tract infection.